| Helicobacter pylori antibody status | CagA+ antibody status | Number of subjects | OR* (95% CI) | OR* (95% CI) | OR* (95% CI) |
| Barrett’s oesophagus/GORD/controls | Barrett’s oesophagus vs controls (without GORD in model) | Barrett’s oesophagus vs controls (with GORD frequency in model)† | Barrett’s oesophagus vs controls (with GORD severity in model)† | ||
| Negative | Negative | 263/225 | 1.00 | 1.00 | 1.00 |
| Positive | Negative | 31/44 | 0.61 (0.35 to 1.04) | 0.80 (0.42 to 1.51) | 1.29 (0.60 to 2.80) |
| Positive | 5/23 | 0.08 (0.02 to 0.35) | 0.08 (0.15 to 0.45) | 0.08 (0.12 to 0.49) | |
| All H pylori-positive subjects‡ | 36/67 | 0.42 (0.26 to 0.70) | 0.54 (0.30 to 0.98) | 0.71 (0.36 to 1.38) |
This analysis evaluates whether the association between H pylori and Barrett’s oesophagus (for Barrett’s oesophagus cases vs population controls) is potentially mediated by the frequency or severity of GORD symptoms.
*Adjusted for gender, age, home facility location, body mass index, ethnicity, smoking status, educational status and multivitamin use. †The GORD severity analysis compared severity among persons with at least weekly GORD with that in persons with no GORD symptoms. Severity was recorded as mild (could be ignored), moderate (could not be ignored, but did not affect lifestyle), severe (could not be ignored and did affect lifestyle) or very severe (markedly affected lifestyle). Frequency was defined as never, less than once a month, once a month, once a week, several times a week or daily. ‡These include both CagA-positive and CagA-negative subjects.
CagA, cytotoxin-associated gene product A; GORD, gastro-oesophageal reflux disease.